Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Breast cancer
Closed
Phase 2
This study is looking at whether immunotherapy in combination with a targeted drug can improve treatment for breast cancer.
It is for people whose cancer is HER2 negative and oestrogen (ER) positive. This means the breast cancer cells:
don’t have receptors for HER2
do have receptors for oestrogen
Recruitment start: 1 January 2018
Recruitment end: 31 March 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Peter Schmid
Queen Mary University of London
F. Hoffmann-La Roche Ltd
Last reviewed: 13 June 2022
CRUK internal database number: 15885
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
